Sartorius Stedim Biotech Shares Fall 2% in a Market Weighed Down by Iran
The French bioproduction equipment specialist falls as the market close approaches, dragged down by a Parisian market heavily penalized by the new military escalation between Washington and Tehran. However, the stock remains above its short-term moving averages, preserving the momentum established since mid-May.
A Measured Decline in an SBF 120 Pulled Down by Geopolitical Tensions
Sartorius Stedim Biotech shares lose 1.95% at €175.80, ranking mid-table in the SBF 120. The broader index is down 2.01% and the CAC 40 declines by 1.99%, following the Dax (-1.69%) and the FTSE 100 (-1.10%). The VIX jumps nearly 12% to 18.06, indicating a marked increase in nervousness following the announcement of US strikes against Iran and Tehran's claimed retaliation against military installations in Kuwait and Bahrain. Donald Trump has also stated from Ankara that the ceasefire with Iran is, in his opinion, over, fueling risk aversion on European markets.
In this tense session context, the stock's decline remains contained compared to the general sector retreat. Today's drop contrasts with the brief upward dynamic observed at the end of June, the stock having already shed part of its late June rebound. Over the quarter, the performance remains positive at +6.35%, while the annual balance remains negative by more than 12%.
A Stock That Holds Its Short-Term Moving Averages Despite Today's Pressure
Despite today's decline, the stock remains above its MM20 at €174.65 (+0.66%) and its MM50 at €170.43 (+3.15%), indicating that the short-term trend is not broken. However, the MM200 at €185.23 remains 5.09% above the current price, reflecting the lag accumulated over the year. The RSI at 57 indicates neutral momentum, without directional excess, and the MACD remains above its signal line (2.10 against 1.46).
The identified support at €161.90 offers a margin relative to the current price, while the resistance at €183.70 remains the next technical threshold to cross to extend the momentum established since mid-May. This level had already been targeted in mid-June, although the breakthrough was not confirmed, as evidenced by a previous attempt. The maintenance of short-term moving averages remains the element to watch if geopolitical tensions prolong the selling pressure on the SBF 120.
